Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies

Women with breast cancer are at a higher risk of developing vulvar and vaginal atrophy (VVA), a major component of the genitourinary syndrome of menopause, due to the combined estrogen-depleting effects of chemotherapy, adjuvant hormone therapy, and menopause. Ospemifene is approved to treat VVA in...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Drugs Context
Asıl Yazarlar: Lilue, Mariella, Palacios, Santiago, del Carmen Pingarrón Santofimia, María
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioExcel Publishing Ltd 2020
Konular:
Case Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7337590/
https://ncbi.nlm.nih.gov/pubmed/32670380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.2020-3-4
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller